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Recent epidemiologic studies indicate that infectious
agents may contribute to some cases of schizophrenia. In
animals, infection with Toxoplasma gondii can alter behav-
ior and neurotransmitter function. In humans, acute infec-
tion with T. gondii can produce psychotic symptoms similar
to those displayed by persons with schizophrenia. Since
1953, a total of 19 studies of T. gondii antibodies in persons
with schizophrenia and other severe psychiatric disorders
and in controls have been reported; 18 reported a higher
percentage of antibodies in the affected persons; in 11
studies the difference was statistically significant. Two other
studies found that exposure to cats in childhood was a risk
factor for the development of schizophrenia. Some medica-
tions used to treat schizophrenia inhibit the replication of T.
gondii in cell culture. Establishing the role of T. gondii in the
etiopathogenesis of schizophrenia might lead to new med-
ications for its prevention and treatment.
S
chizophrenia is a pervasive neuropsychiatric disease
of uncertain cause that affects approximately 1% of
the adult population in the United States and Europe. An
increased occurrence of schizophrenia in family members
of affected persons suggests that genetic factors play a
role in its etiology, and some candidate predisposing
genes have been identified. Environmental factors are also
important. Epidemiologic studies, for example, have
established that winter-spring birth, urban birth, and peri-
natal and postnatal infection are all risk factors for the dis-
ease developing in later life. These studies have rekindled
an interest in the role of infectious agents in schizophre-
nia, a concept first proposed in 1896 (1). This review
focuses on evidence specifically linking infection with
Toxoplasma gondii to the etiology of some cases of
schizophrenia.
T. gondii is an intracellular parasite in the phylum
Apicomplexa. Its life cycle can be completed only in cats
and other felids, which are the definitive hosts. However, T.
gondii also infects a wide variety of intermediate hosts,
including humans. In many mammals, T. gondii is known
to be an important cause of abortions and stillbirths and to
selectively infect muscle and brain tissue. Avariety of neu-
rologic symptoms, including incoordination, tremors, head-
shaking, and seizures, have been described in sheep, pigs,
cattle, rabbits, and monkeys infected with T. gondii (2).
Humans may become infected by contact with cat feces
or by eating undercooked meat. The importance of these
modes of transmission may vary in different populations
(3). Individual response to Toxoplasma infection is deter-
mined by immune status, timing of infection, and the
genetic composition of the host and the organism (4).
Toxoplasma organisms have also been shown to impair
learning and memory in mice (5) and to produce behav-
ioral changes in both mice and rats. Of special interest are
studies showing that Toxoplasma-infected rats become less
neophobic, leading to the diminution of their natural aver-
sion to the odor of cats (6). These behavioral changes
increase the chances that the rat will be eaten by a cat, thus
enabling Toxoplasma to complete its life cycle, an example
of evolutionarily driven manipulation of host behavior by
the parasite.
In humans, Toxoplasma is an important cause of abor-
tions and stillbirths after primary infection in pregnant
women. The organism can also cross the placenta and
infect the fetus. The symptoms of congenital toxoplasmo-
sis include abnormal changes in head size (hydrocephaly
or microcephaly), intracranial calcifications, deafness,
seizures, cerebral palsy, damage to the retina, and mental
retardation. Some sequelae of congenital toxoplasmosis
are not apparent at birth and may not become apparent
until the second or third decade of life. Hydrocephalus (7),
increased ventricular size (8), and cognitive impairment
(9) have also been noted in some persons with schizophre-
nia and other forms of psychosis.
Some cases of acute toxoplasmosis in adults are associ-
ated with psychiatric symptoms such as delusions and hal-
lucinations. Areview of 114 cases of acquired toxoplasmo-
sis noted that “psychiatric disturbances were very fre-
quent” in 24 of the case-patients (10). Case reports
describe a 22-year-old woman who exhibited paranoid and
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Maryland, USAbizarre delusions (“she said she had no veins in her arms
and legs”), disorganized speech, and flattened affect; a 32-
year-old woman who had auditory and visual hallucina-
tions; and a 34-year-old woman who experienced auditory
hallucinations and a thought disorder (11). Schizophrenia
was first diagnosed in all three patients, but later neurolog-
ic symptoms developed, which led to the correct diagnosis
of Toxoplasma encephalitis.
Psychiatric manifestations of T. gondii are also promi-
nent in immunocompromised persons with AIDS in whom
latent infections have become reactivated. Reviews of such
AIDS cases with toxoplasmosis have indicated that altered
mental status may occur in as many as 60% of patients and
that the symptoms may include delusions, auditory hallu-
cinations, and thought disorders (12).
Additional studies have documented that persons with
serologic evidence of Toxoplasma infection have evidence
of psychiatric changes in the absence of a history of clini-
cally apparent Toxoplasma infection. Studies in which per-
sonality questionnaires have been administered to healthy
adults have indicated that serum antibodies to T. gondii are
associated with alterations in behavior and psychomotor
skills (13). Seropositivity to Toxoplasma has also been
associated with “lack of energy or tiredness” in school-
children (14). In view of these findings, we decided to
carry out serologic and other studies and to survey the lit-
erature for possible additional links between Toxoplasma
infection and schizophrenia.
Serologic Studies of Patients with Schizophrenia
Studies Before 1980
In the course of doing our studies, we discovered that
much research had been published in languages other than
English and was not listed on searchable databases.
Through direct contact with authors and by obtaining refer-
ences listed on their papers, we identified 13 relevant stud-
ies published between 1953 and 1979 (15–27), as listed on
the Table. Some publication bias is likely, since negative
studies are less likely to have been submitted or published.
The 13 studies used a variety of immunologic methods
for measuring antibodies, including the Sabin Feldman dye
test, skin tests, and complement fixation (CF). One study
used a test in which an alkaloid from T. gondii caused a
tropical fish, Lebistes reticulatus, to change color (19).
Some of the studies compared the relative efficacy of two
different tests. Most of the studies defined Toxoplasma-
positive results as the presence of a skin reaction or anti-
bodies above a certain titer but often without specifying
the precise details of the method; thus, comparing the older
studies with each other was not possible. Most of these
studies also did not specify what diagnostic criteria were
used for schizophrenia, but since at least 12 of them used
inpatients, the patients likely had a severe psychiatric dis-
order. Similarly, most of the studies did not specify the ori-
gin of their control group other than saying such things as
“681 healthy persons working or studying in the city of
Gdansk” (15).
Despite these limitations, 12 of the 13 studies found that
the patient group had a higher percentage of antibodies to
Toxoplasma than the control group. In eight of the studies,
the increase was statistically significant by chi square at the
level of p < 0.05. In the two largest studies, Kozar (15) in
Poland reported antibodies in 495 (52%) of 961 psychiatric
inpatients compared with 170 (25%) of 681 controls, and
Roch and Varela (25) in Mexico found antibodies in 836
(86%) of 973 patients with schizophrenia compared with
finding antibodies in 30% of the general population.
Studies Since 1999
We identified no studies that were done between 1979
and 1999. Since that time, six studies have been carried
out, including our own (28–32). All used enzyme
immunoassay methods for measuring antibodies to
Toxoplasma. All of the studies also used modern diagnos-
tic criteria for schizophrenia; three studies included
patients with chronic disease, and three included patients
who were in the first episode of the disease. All of the stud-
ies identified their control groups, and some attempts were
made to match them to the patient groups.
The results of these studies are summarized in the
Table. In all of the studies, the patients had more antibod-
ies to Toxoplasma than the control groups, and in the three
studies, carried out in China and Germany, of patients who
were having their first-episode of schizophrenia, the differ-
ences were statistically significant. One of the first-episode
studies, carried out in Cologne by Leweke et al. (32),
divided the first-episode patients into those who had never
received antipsychotic treatment and those who had
received some treatment. The antibody levels for the treat-
ed group were intermediate between the levels of the
never-treated group and those of the control group, sug-
gesting that antipsychotic medication may have decreased
the antibody levels. This conclusion is supported by a
study that indicated that some antipsychotic medications
inhibit the growth of T. gondii in cell culture (33).
The Leweke et al. study also collected cerebrospinal
fluid (CSF) from the first-episode patients. The level of
Toxoplasma antibody in the CSF of untreated patients was
significantly higher than the normal controls (p < 0.0001)
(32). Treated first-episode patients had CSF antibody lev-
els intermediate between those of the untreated patients
and the controls, just as was found for the sera.
In addition to these studies on adults with schizophre-
nia, a study was also conducted by analyzing serum sam-
ples from pregnant women, obtained shortly before deliv-
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other psychoses developed. Preliminary analysis indicates
an increased rate of immunoglobulin (Ig) M (but not IgG)
class antibodies to Toxoplasma gondii in mothers with
infants in whom schizophrenia developed later, suggesting
that the mothers were experiencing an active infection or
that they had persistent IgM antibodies, as described in
other studies. Increased levels of IgM antibodies were not
found to other perinatal pathogens such as rubella virus or
cytomegalovirus (34).
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Table. Toxoplasmosis antibody studies of psychiatric patients  
Y  Author and country  Test used  Patients  Controls 
% Patients 
antibody positive 
% Controls 
antibody positive 
p value 
chi square 
Before 1980 
1953  Kozar (15) 
Poland 
Skin test  Psychiatric 
inpatients, all 
diagnoses 
Healthy persons, 
ages 18–60 
52 (495/961)  25 (170/681)  <0.0001 
1956  Vojtechovská et al. 
(16) 
Czechoslovakia 
Skin test  Inpatients with 
“psychosis” 
General 
population 
59 (68/116)  30 (not specified)  <0.0001 
1956  Wende (17) 
East Germany 
Dye test  Inpatients with 
schizophrenia 
Inpatients with 
neurologic 
disorders 
8 (3/38)  5 (24/520)  0.418 
1957  Jirovec et al. (18) 
Czechoslovakia 
Skin test  Inpatients with 
schizophrenia 
Normal 
population 
48 (238/501)  29 (286/970)  <0.0001 
1958  Buentello (19) 
Mexico 
Color change 
in fish 
Inpatients with 
schizophrenia 
Normal subjects  69 (29/42)  0 (0/60)  <0.0001 
1958  Caglieris (20) 
Italy 
Dye test  Inpatients with 
schizophrenia 
Normal subjects  21 (13/61)  15 (12/81)  0.376 
1961  Cook & Derrick (21) 
Australia 
Dye test 
C.F. 
Inpatients with 
schizophrenia 
General 
population 
36 (19/53) ≥1:16 
11 (6/53) ≥1:4 
24 (182/760) 
13 (99/760) 
0.053 
0.840 
1962  Yegerov et al. (22) 
Russia 
Skin test 
C.F. 
Inpatients with 
schizophrenia 
Hospital 
employees 
19 (7/37) 
32 (12/37) 
4 (1/25) 
28 (7/25) 
0.124 
0.784 
1962  Avlavidov (23) 
Bulgaria 
 
Skin test 
C.F. 
Psychiatric 
inpatients, not 
specified 
Female surgical 
patients 
26 (5/19) 
21 (3/14) 
3 (1/35) 
9 (3/34) 
0.017 
0.339 
1966  Berengo et al. (24) 
Italy 
Dye test  Inpatients with 
schizophrenia 
General 
population 
14 (76/560)  4 (49/1200)  <0.0001 
1966  Roch & Varela (25) 
Mexico 
Dye test  Schizophrenia, 
hospital status not 
specified 
General 
population 
86 (836/973)  30 (4,411/14,689)  <0.0001 
1968  Garrido & Redondo 
(26) Spain 
C.F.  Inpatients with 
schizophrenia 
General 
population 
44 (17/39)  29 (147/500)  0.072 
1979  Garcia (27) 
Cuba 
Skin test  Psychiatric 
inpatients 
Normal persons  60 (60/100)  30 (30/100)  <0.0001 
Since 1999 
1999  Qiuying et al. (28) 
China 
EIA  Inpatients with 
schizophrenia 
Normal persons 
from same region 
for routine 
physicals 
14 (22/152)  10 (41/396)  0.181 
2001  Gu et al. (29) 
China 
EIA  First-episode 
schizophrenia 
Normal controls 
matched for age, 
sex, birthplace 
33 (45/135)  9 (4/43)  0.002 
2001  Yolken et al. (30) 
Germany 
EIA: IgG or 
IgM 
First-episode 
schizophrenia 
Normal controls 
matched for age, 
sex, SES 
42 (16/38)  11 (3/27)  0.007 
2002  Boronow et al. (31) 
United States 
EIA  Outpatients with 
schizophrenia 
Normal controls 
matched for age 
12 (28/229)  7 (7/100)  0.147 
2003  Leweke et al. (32) 
Germany 
EIA  First-episode 
schizophrenia, 
never treated 
Normal controls 
matched for age, 
sex, SES 
36 (13/36)  14 (10/73)  <0.007 
2003  Torrey & Yolken 
(unpub. data) 
Ireland 
EIA  Inpatients with 
schizophrenia 
Hospital 
employees 
60 (31/52)  45 (9/20)  0.299 
aC.F., complement fixation; EIA, enzyme immunoassay; Ig, immunoglobulin; SES, socioeconomic status. Discussion
Multiple studies have demonstrated that the brains of
persons with schizophrenia show structural and functional
changes and that these exist even in patients who have
never been treated with antipsychotic medications (35).
Thus, schizophrenia, like multiple sclerosis and Parkinson’s
disease, is a chronic disease of the central nervous system;
as with other such diseases, infectious agents should be
considered as possible etiologic agents, perhaps in persons
who also have an increased genetic susceptibility.
T. gondii is of special interest because of its known
affinity for brain tissue and its capacity for long-term
infection starting in early life. The effect of Toxoplasma
infection on any given person may differ, depending on
such factors as individual genetic predisposition, the state
of the immune system, the dose, the virulence of the infect-
ing strain, the timing (e.g., infections in the first trimester
of pregnancy differ from those in the third trimester; pre-
natal and postnatal infections differ; etc.), and the part of
the brain affected.
If Toxoplasma is involved in the etiology of schizophre-
nia, however, its synergy with genes may determine the
person’s brain development, immune response to infec-
tions, and response to other infectious agents. The fact that
T. gondii has been shown to activate retroviruses in animal
model systems may be relevant (36). This property is con-
sistent with the recent finding that many persons with
schizophrenia exhibit increased retroviral activation with-
in their central nervous systems (37).
Numerous studies indicate that, although the symptoms
of schizophrenia generally do not manifest until late ado-
lescence or early adulthood, the disease process has its ori-
gins in earlier stages of brain development. The ability of
Toxoplasma organisms to infect the perinatal brain is thus
consistent with this aspect of schizophrenia pathogenesis.
However, prospective studies also support a possible role
of postnatal infections in some cases of schizophrenia (38).
The potential effects of the transmission of Toxoplasma in
early childhood or later in life should thus be considered.
Epidemiologically, two studies have reported that
adults who have schizophrenia or bipolar disorder had a
greater exposure to cats in childhood. In one study, 84
(51%) of the 165 affected versus 65 (38%) of the 165
matched controls had owned a house cat in childhood (p =
0.02) (39). In the other study, 136 (52%) of the 262 affect-
ed versus 219 (42%) of the 522 matched controls owned a
cat between birth and age 13 (odds ratio 1.53; p < 0.007)
(40). Whether any geographic association exists between
the prevalence of toxoplasmosis and the prevalence of
schizophrenia is unknown. France, which has a high preva-
lence of Toxoplasma-infected persons, was reported to
have first-admission rates for schizophrenia approximate-
ly 50% higher than those in England (41). Ireland also has
a high rate of Toxoplasma-infected persons in rural areas
(42), confirmed by the high rate of infection in hospital
personnel in our own study. The area of our study in
Ireland has also been reported to have a high prevalence of
schizophrenia (43).
Neuropathologically, studies of T. gondii in cell culture
have shown that glial cells, especially astrocytes, are selec-
tively affected (44,45). Postmortem studies of schizo-
phrenic brains have also reported many glial abnormalities
(46), including decreased numbers of astrocytes (47).
Similarly, animal studies of Toxoplasma infections have
demonstrated that this organism affects levels of dopamine,
norepinephrine, and other neurotransmitters, which are
well known to be affected in persons with schizophrenia.
Few data exist concerning the clinical correlates of
Toxoplasma infection in persons with schizophrenia. A
recent study found that persons with schizophrenia who
have serologic evidence of Toxoplasma infection have
increased levels of cognitive impairment compared to age-
matched  Toxoplasma-seronegative patients with similar
degrees of psychotic symptoms (31). Additional studies
are needed on the possible associations between
Toxoplasma infections and the symptoms or clinical course
of schizophrenia and other psychiatric diseases.
One limitation of studies of Toxoplasma infection and
schizophrenia is that one cannot conclusively rule out dis-
ease-related differential exposure to the organism. Thus,
hospitalized patients may be fed undercooked meat, there-
by increasing their seropositivity. Alternatively, the authors
of one of the studies speculated that the increased patient
seropositivity might have been because the patients
worked in the hospital gardens, which were also frequent-
ed by cats (21). The possible effects of hospitalization,
altered behavior, or other artifactual factors on seropositiv-
ity can be minimized by the analysis of persons with the
recent onset of symptoms, as three studies described above
have done.
Studies are ongoing in attempts to better define the rela-
tionship of Toxoplasma infection to schizophrenia. An ini-
tial study of the orbital frontal cortex of 14 persons with
schizophrenia (48), in which primers to T. gondii were
used, did not detect sequences. Studies should also include
organisms such as Neospora caninum and  Hammondi
hammondi,  which are closely related to T. gondii and
which cross-react serologically (49); N. caninum has been
detected in human specimens in our laboratory and by oth-
ers (50). The use of organism-specific antigens generated
from molecular cloning and the use of stage-specific anti-
bodies should help elucidate both the specificity and the
timing of the infection.
Finally, clinical trials are under way of antimicrobial
drugs with anti-Toxoplasma activity, such as trimethoprim-
sulfamethoxazole and azithromycin, as adjunctive treat-
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These studies may lead to new methods for the treatment
of schizophrenia and other psychiatric disorders that may
be associated with Toxoplasma and related organisms.
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